Benowitz Brooke, Payne Katherine S, Wintrode Megan, Keyes Reilly, Levenson Ashley, Fisher Evan P, Combs Alex Q, Kent G Whitman, Kamm Janina M, Soble Jason R
Department of Psychiatry, University of Illinois College of Medicine, Chicago, IL, USA.
Department of Psychology, The Chicago School, Chicago, IL, USA.
Appl Neuropsychol Adult. 2025 Aug 21:1-7. doi: 10.1080/23279095.2025.2548011.
Research examining performance (PVTs) and symptom (SVTs) validity tests has largely included freestanding SVTs or SVTs included in lengthy personality inventories, whereas few studies have assessed this relationship using embedded SVTs. This study investigated the concordance between newly developed embedded SVTs derived from the Beck Depression Inventory-Second Edition (BDI-II) and Beck Anxiety Inventory and performance validity status.
A mixed clinical sample of 420 adult medical and neuropsychiatric patients referred for outpatient neuropsychological evaluation at an urban academic medical center. Performance validity status was determined by the Dot Counting Test, Medical Symptom Validity Test, WAIS-IV Reliable Digit Span, and Test of Memory Malingering-Trial 1. Symptom validity status was determined by SVTs validated from the BDI-II and BAI total scores.
BDI-II and BAI SVTs were moderately correlated (=.69), whereas weak correlations emerged between these embedded SVT and PVTs (=.09-.22). Patients with invalid performance on PVTs had significantly higher elevations rates on the BDI-II (2.5x) and BAI (2x) SVTs. However, neither the BDI-II nor BAI SVTs, as well as a combined BDI-II/BAI composite score accurately differentiated invalid from valid performance validity status (AUCs=.573-.583). Results essentially replicated after supplementary analyses excluding those with 1 PVT failure.
Results align with previous research showing that that PVTs and newly-developed embedded SVTs in the BDI-II and BAI assess non-redundant constructs and should both be routinely included in neuropsychological evaluations. In short, performance invalidity does not necessarily convey noncredible symptom reporting and vice versa.
关于表现效度测试(PVTs)和症状效度测试(SVTs)的研究主要包括独立的SVTs或包含在冗长人格量表中的SVTs,而很少有研究使用嵌入式SVTs来评估这种关系。本研究调查了从贝克抑郁量表第二版(BDI-II)和贝克焦虑量表中衍生出的新开发的嵌入式SVTs与表现效度状态之间的一致性。
选取了420名成年医学和神经精神科患者的混合临床样本,这些患者在一家城市学术医疗中心接受门诊神经心理学评估。通过点数测试、医学症状效度测试、韦氏成人智力量表第四版可靠数字广度测试和记忆伪装测试-试验1来确定表现效度状态。通过从BDI-II和BAI总分中验证的SVTs来确定症状效度状态。
BDI-II和BAI的SVTs呈中度相关(r =.69),而这些嵌入式SVT与PVTs之间的相关性较弱(r =.09-.22)。PVTs表现无效的患者在BDI-II(2.5倍)和BAI(2倍)的SVTs上的升高率显著更高。然而,BDI-II和BAI的SVTs以及BDI-II/BAI综合得分均未能准确区分无效和有效的表现效度状态(曲线下面积=.573-.583)。在排除有1次PVT失败的患者进行补充分析后,结果基本重复。
结果与先前的研究一致,表明PVTs以及BDI-II和BAI中新开发的嵌入式SVTs评估的是非冗余结构,两者都应常规纳入神经心理学评估。简而言之,表现无效并不一定意味着症状报告不可信,反之亦然。